The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline. Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive ...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable ...

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 102.8% in the past year, fueled by strong revenue and earnings ...

Teva Pharmaceutical Industries ( TEVA +1.23%) will unveil its first-quarter results this Wednesday, April 29. Many Teva ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the transformative ...

The olanzapine long-acting injectable (TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1administered ...

Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding ...

This deal falls under Teva’s wider strategy to prioritise strategic, financially diligent deals around de-risked, differentiated, late-stage assets.

The Israeli pharmaceutical giant is accelerating its growth strategy and adding to its portfolio a groundbreaking treatment for Tourette syndrome in children.

Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. The ...

Teva Pharmaceutical Industries (NYSE: TEVA) will unveil its first-quarter results this Wednesday, April 29. Many Teva trackers will be watching for validation of the company's continuing strategic ...